Chris Raymond
Stock Analyst at Raymond James
(2.92)
# 1,382
Out of 5,182 analysts
9
Total ratings
66.67%
Success rate
50.01%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Chris Raymond
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MNPR Monopar Therapeutics | Downgrades: Outperform | $142 → $123 | $57.92 | +112.36% | 3 | Nov 14, 2025 | |
| SION Sionna Therapeutics | Initiates: Strong Buy | $45 | $38.89 | +15.71% | 1 | Sep 3, 2025 | |
| TYRA Tyra Biosciences | Initiates: Strong Buy | $35 | $36.69 | -4.61% | 1 | Sep 3, 2025 | |
| NUVL Nuvalent | Initiates: Outperform | $105 | $104.59 | +0.39% | 1 | Sep 3, 2025 | |
| KLRS Kalaris Therapeutics | Initiates: Strong Buy | $23 | $6.07 | +278.91% | 1 | Sep 3, 2025 | |
| COGT Cogent Biosciences | Initiates: Strong Buy | $30 | $37.35 | -19.68% | 1 | Sep 3, 2025 | |
| BHVN Biohaven | Initiates: Strong Buy | $75 | $9.39 | +698.72% | 1 | Sep 3, 2025 |
Monopar Therapeutics
Nov 14, 2025
Downgrades: Outperform
Price Target: $142 → $123
Current: $57.92
Upside: +112.36%
Sionna Therapeutics
Sep 3, 2025
Initiates: Strong Buy
Price Target: $45
Current: $38.89
Upside: +15.71%
Tyra Biosciences
Sep 3, 2025
Initiates: Strong Buy
Price Target: $35
Current: $36.69
Upside: -4.61%
Nuvalent
Sep 3, 2025
Initiates: Outperform
Price Target: $105
Current: $104.59
Upside: +0.39%
Kalaris Therapeutics
Sep 3, 2025
Initiates: Strong Buy
Price Target: $23
Current: $6.07
Upside: +278.91%
Cogent Biosciences
Sep 3, 2025
Initiates: Strong Buy
Price Target: $30
Current: $37.35
Upside: -19.68%
Biohaven
Sep 3, 2025
Initiates: Strong Buy
Price Target: $75
Current: $9.39
Upside: +698.72%